IGF-1 DES: proposed mechanism and missing clinical evidence
Clinical review pending
IGF-1 DES is an experimental growth-factor analogue. Data come from laboratory and animal studies; a muscle-building benefit in humans has not been established.
What is IGF-1 DES?
IGF-1 DES, short for DES(1-3) IGF-1, is a modified form of insulin-like growth factor 1. It lacks the first three amino acids. As a result, it binds less strongly to the proteins that normally regulate natural IGF-1 and has stronger effects in laboratory systems. It is sold as a “research chemical” and used for performance enhancement or muscle building. It is not an approved medicine. Source
How is it intended to work?
IGF-1 DES acts at the IGF-1 receptor, whose signaling pathway is involved in muscle protein synthesis and tissue growth. Its reduced binding to carrier proteins 1 is thought to produce stronger local activity than natural IGF-1. Rodent studies have observed improved nitrogen balance and reduced muscle protein breakdown. In cell culture, it serves as a potent growth stimulus. This does not establish a benefit in humans. Mecasermin, by contrast, is a different product containing full-length IGF-1 and is approved as a medicine for a rare growth disorder; IGF-1 DES is a separate, unapproved analogue. Source
Is it FDA-approved?
According to the source article, IGF-1 DES is not FDA-approved and has no approved status for compounding. It is used as a research chemical and for performance enhancement. In sport, IGF-1 and its analogues are prohibited at all times under the WADA list.
What does the research show?
The evidence is preclinical. An animal study indexed in PubMed 2 reported improved nitrogen balance and reduced protein breakdown. The peptide is also used as a potent reagent in cell-growth experiments. Clinical trials establishing a benefit for muscle building or performance enhancement in humans are lacking.
References provided in the source article
Sources: an animal study of IGF-1 and protein metabolism (Martin et al., American Journal of Physiology, 1991, DOI: 10.1152/ajprenal.1991.261.4.F626 2 ) and a review of performance peptides (Dominikowski et al., Frontiers in Endocrinology, 2026, DOI: 10.3389/fendo.2026.1822475 3 ), indexed on PubMed; and the WADA Prohibited List.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.